OriA631-B (a CD39/PD-L1 bispecific antibody) displays potent anti-tumor efficacy in syngeneic MC38 and Hepa1-6 models through the dual blockade of CD39-mediated immunosuppression and PD-L1-dependent T cell exhaustion, while also demonstrating a favorable safety profile [247]. Here, ENTPD1 is linked to neoplasm.